n = 15 ) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure ( t-AML , 30.4 % , n = 69 ; breast cancer patients , 27.2 % , n = 22 ) .
O O O O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature O O B-OrganismTaxon O O O O O I-DiseaseOrPhenotypicFeature O O O O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature B-OrganismTaxon O O O O O O O O O